Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT06112171

Comparison of a Lithotripsy vs Standard Preparation Followed by Stenting With Supera Stent in Femoropopliteal Lesions

Led by University of Leipzig · Updated on 2026-05-06

120

Participants Needed

1

Research Sites

463 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This study is an investigator-initiated, prospective, single-center, 1:1 randomized pilot study. The trial evaluates the safety and efficacy of intravascular lithotripsy in comparison to standard lesion preparation using standard and/or high-pressure balloon angioplasty in patients with femoropopliteal artery disease. All patients will receive subsequent Supera stent implantation at the operator's discretion. Additional standard nitinol bare metal stent (BMS), drug-eluting stent or covered stent implantation is at the operator's discretion. Patients will be stratified for total occlusions.

CONDITIONS

Official Title

Comparison of a Lithotripsy vs Standard Preparation Followed by Stenting With Supera Stent in Femoropopliteal Lesions

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 years or older
  • Signed informed consent approved by Medical Ethics Committee
  • Willingness to attend follow-up visits and complete required testing
  • Rutherford Classification between 2 and 5
  • Presence of a de novo or restenotic lesion in the superficial femoral artery and/or popliteal artery with 70% or greater stenosis
  • No previous stent in the target lesion or previously stented vessel with stents at least 3 cm apart
  • Target lesion length of at least 10 cm
  • Severe calcification on fluoroscopy defined by PACSS Grade 4 with bilateral calcification extending 50 mm or more
  • Multiple lesions with a maximum 3 cm healthy vessel segment in between may be treated as one lesion
  • Reference vessel diameter between 4 mm and 6.5 mm
  • At least one infrapopliteal artery with less than 50% diameter stenosis connected to the native femoropopliteal artery
  • Successful guidewire crossing of the target treatment segment
Not Eligible

You will not qualify if you...

  • Failure to successfully cross the target lesion with a guidewire
  • Presence of fresh thrombus in the lesion
  • Presence of aneurysm in the target vessel(s)
  • Presence of a stent in the target lesion less than 3 cm from any previous stent
  • Prior vascular surgery on the target lesion
  • Stroke or heart attack within 3 months prior to enrollment
  • Participation in another investigational drug, device, or biologic study that has not reached its primary endpoint
  • Life expectancy less than one year
  • Known allergies or sensitivity to heparin, aspirin, other anticoagulants/antiplatelet therapies, or contrast media that cannot be treated beforehand
  • Rutherford Classification of 0, 1, or 6
  • Significant gastrointestinal bleeding or coagulopathy contraindicating antiplatelet therapy
  • Receiving immunosuppressant therapy
  • Pregnant or breastfeeding females
  • History of major amputation above the ankle in the same limb as the target lesion

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

University Clinic Leipzig

Leipzig, Saxony, Germany, 04103

Actively Recruiting

Loading map...

Research Team

S

Sabine Steiner, Prof. Dr.

CONTACT

J

Janine Brunotte

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here